NasdaqGM - Nasdaq Real Time Price ? USD Sage Therapeutics, Inc. (SAGE) Follow Compare 7.65 -0.14 (-1.80%) At close: October 22 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Sage Therapeutics (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 20 hours ago SAGE -1.80% State Street Corp's Strategic Acquisition of Sage Therapeutics Shares On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 451,377 shares of Sage Therapeutics Inc (NASDAQ:SAGE) at a price of $7.22 per share. This transaction increased State Street Corp's total holdings in Sage Therapeutics to 2,926,239 shares, marking a notable expansion in their investment in the biotechnology sector. State Street Corp, headquartered at One Lincoln Street, Boston, MA, is a prominent financial services provider known for its robust investment strategies. GuruFocus.com ? 4 days ago SAGE -1.80% STT Sage Therapeutics to Reduce Workforce by 33%, Stock Down SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading. Zacks ? 4 days ago SAGE -1.80% Sage lays off 55% of R&D workforce and refocuses pipeline Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s cash runway. Pharmaceutical Technology ? 5 days ago SAGE -1.80% Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline Sage Therapeutics cuts 33% of its workforce to support ZURZUVAE launch and focus on pipeline development GuruFocus.com ? 5 days ago SAGE -1.80% After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce On Thursday, Sage Therapeutics, Inc. (NASDAQ:SAGE) announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) in postpartum depression. The reorganization is intended to enable Sage to strengthen its balance sheet, extend its cash runway, and position the company for long-term growth potential. The reorganization is planned to be substantially completed by the end of the fourth quarter of 2024. The company will lay off over 165 employee Benzinga ? 5 days ago SAGE -1.80% BIIB Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard. The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term growth. Barrons.com ? 5 days ago SAGE -1.80% Sage to cut one-third of workforce, streamline drug pipeline The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives. BioPharma Dive ? 5 days ago SAGE -1.80% Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE? Commercialization and Focus its Development Portfolio CAMBRIDGE, Mass., October 17, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline development efforts ahead of a clinical study readout for dalzanemdor in Huntington’s Disease expected later this year. The reorganization is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth pot Business Wire ? 5 days ago SAGE -1.80% Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 CAMBRIDGE, Mass., October 15, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. Business Wire ? 8 days ago SAGE -1.80% Sage Therapeutics price target lowered to $8 from $9 at Wedbush Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm notes Sage reported the Phase 2 LIGHTWAVE study of dalzanemdor in mild AD/MCI failed to demonstrate a statistical significance improvement from baseline on the primary endpoint of change in WAIS-IV score. Wedbush acknowledges that this was not an opportunity it previously incorporated in its estimates so nothing to remove. Sage will discontinue further efforts for dalzane TipRanks ? 12 days ago SAGE -1.80% SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal. Zacks ? 13 days ago SAGE -1.80% Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s. Barrons.com ? 14 days ago SAGE -1.80% After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD). The LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84 Benzinga ? 14 days ago SAGE -1.80% Sage continues downslide as Alzheimer’s study fails After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes. BioPharma Dive ? 14 days ago SAGE -1.80% Sage Therapeutics stock drops after disappointing Alzheimer's trial results Investing.com -- Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). Investing.com ? 14 days ago SAGE -1.80% Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease CAMBRIDGE, Mass., October 08, 2024--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD). The LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on th Business Wire ? 15 days ago SAGE -1.80% Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock. Zacks ? 15 days ago SAGE -1.80% Sector Update: Health Care Stocks Steady Late Afternoon Sector Update: Health Care Stocks Steady Late Afternoon PREMIUM MT Newswires ? 18 days ago TMO JNJ SAGE -1.80% Sector Update: Health Care Stocks Softer Friday Afternoon Sector Update: Health Care Stocks Softer Friday Afternoon PREMIUM MT Newswires ? 18 days ago TMO SAGE -1.80% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SAGE S&P 500 YTD -64.70% +22.67% 1-Year -58.42% +38.52% 3-Year -81.45% +28.60%
